title: Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue.
abstract: Fulvestrant (Faslodex) is administered by intramuscular injection and is converted into ketone, sulfate, sulfone and glucuronide metabolites. Glucuronidation, catalyzed by 18 members of the UDP-glucuronosyltransferase (UGT) enzyme family, plays a major role in the elimination of natural estrogens. The present study was aimed at identifying and characterizing human UGT enzymes involved in the glucuronidation of this antiestrogen as well as other synthetic estrogen derivatives with aliphatic chains on the E2 molecule. In contrast to E2, which is conjugated by UGT1A1, -1A3, -1A8, -1A10, and -2B7, fulvestrant is glucuronidated by UGT1A1, -1A3, -1A4, and -1A8. The four UGT1A-fulvestrant conjugating enzymes glucuronidate this substrate at position 3, whereas only UGT1A8 also produces fulvestrant-17-glucuronide. For E2, only UGT1A3 and UGT2B7 are capable to conjugate at 17-hydroxyposition. These observations indicate that addition of an aliphatic chain to the E2 molecule modifies the specificity of the UGT enzymes toward the C18 molecules. To further investigate the specificity of these enzymes, a series of E2 derivatives with aliphatic or phenyl chains at position 2, 7alpha, and 11beta was also tested for its conjugation with human UGT enzymes. It was observed that, in addition to UGT1A3, UGT1A1 and UGT1A8 also played important roles for the glucuronidation of these compounds. This suggests that the basic structure of E2 is one of the major determinants for the glucuronidation catalyzed by this group of enzymes. Considering the high level of UGT1A3 and -1A4 expression in the gastrointestinal tract and mammary gland, our results suggest that fulvestrant can be inactivated both in intestine and in its target tissue.
authors.affiliation: Oncology and Molecular Endocrinology Research Center, Centre Hospitalier Universitaire de Québec Research Center, Faculty of Medicine, Québec City, Canada.
authors.forename: Sarah
authors.initials: S
authors.lastname: Chouinard
authors.forename: Mélanie
authors.initials: M
authors.lastname: Tessier
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Vernouillet
authors.forename: Sylvain
authors.initials: S
authors.lastname: Gauthier
authors.forename: Fernand
authors.initials: F
authors.lastname: Labrie
authors.forename: Olivier
authors.initials: O
authors.lastname: Barbier
authors.forename: Alain
authors.initials: A
authors.lastname: Bélanger
mesh_terms: D001940:Breast / Q000201:enzymology*; D002478:Cells, Cultured; D004958:Estradiol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D004965:Estrogen Antagonists / Q000737:chemistry / Q000378:metabolism*; D004967:Estrogens / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D000077267:Fulvestrant; D014453:Glucuronosyltransferase / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007082:Ileum / Q000201:enzymology; D007583:Jejunum / Q000201:enzymology; D008099:Liver / Q000201:enzymology
chemical_list: D004965:Estrogen Antagonists; D004967:Estrogens; D000077267:Fulvestrant; D004958:Estradiol; D014453:Glucuronosyltransferase